Zobrazeno 1 - 10
of 110
pro vyhledávání: ''
Autor:
Chana Weinstock, Laleh Amiri-Kordestani, Xiao Hong Chen, Elaine Chang, Eias Zahalka, Jeanne Fourie Zirkelbach, Shenghui Tang, Amna Ibrahim, Mallorie H. Fiero, Julia A. Beaver, Kirsten B. Goldberg, Vishal Bhatnagar, Miao Zhao, Paul G. Kluetz, Richard Pazdur, Tiffany K. Ricks, Jingyu Yu, Junshan Qiu, Lijun Zhang
Publikováno v:
Clin Cancer Res
On March 10, 2021, the FDA granted regular approval to tivozanib for treatment of patients with relapsed or refractory (R/R) advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. Approval was based on the TIVO-3 study, a
Autor:
Manisha Palta, Kent J. Weinhold, Brian G. Czito, David M. Brizel, John S. Yi, April K.S. Salama, Christel Rushing, Douglas S. Tyler, Brent A. Hanks, Georgia M. Beasley, David S. Yoo, Paul J. Mosca, Kristen N. Linney, M. Angelica Selim, Chelsae Dumbauld, Katelyn N. Steadman, Walter T. Lee
Publikováno v:
Clin Cancer Res
Purpose:In this prospective trial, we sought to assess the feasibility of concurrent administration of ipilimumab and radiation as adjuvant, neoadjuvant, or definitive therapy in patients with regionally advanced melanoma.Patients and Methods:Twenty-
Autor:
Xiao-Ou Shu, Ingrid A. Mayer, Wei Zheng, Christina E. Bailey, Jennifer A. Pietenpol, Fei Wang
Publikováno v:
Cancer Research. 81:1163-1170
It is unclear whether racial/ethnic disparities in triple-negative breast cancer (TNBC) mortality remain after accounting for clinical characteristics, treatment, and access-to-care–related factors. In this study, women with a primary diagnosis of
Autor:
Anthony Serritella, Bryan Peterson, Stephanie Moya, Yan Wang, Natalie Reizine, Joseph Thomas, Carol Tan, Katherine I. Zhou, Daniel V.T. Catenacci
Publikováno v:
Clin Cancer Res
Purpose: Intrapatient heterogeneity of programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) could influence their roles as predictive biomarkers for response to immune checkpoint inhi
Autor:
Ilker Y. Eyüpoglu, Klaus Podar, Andreas Stadlbauer, Franz Marhold, Melitta Kitzwögerer, Thomas M. Kinfe, Stefan Oberndorfer, Gertraud Heinz, Max Zimmermann, Michael Buchfelder
Publikováno v:
Clinical Cancer Research. 27:1641-1649
Purpose: Insufficient control of infiltrative glioblastoma (GBM) cells is a major cause of treatment failure and tumor recurrence. Hence, detailed insights into pathophysiologic changes that precede GBM recurrence are needed to develop more precise n
Autor:
Frankie A. Holmes, Laura Biganzoli, Catherine M. Kelly, Zhou Zhu, Maureen E. Trudeau, Patrick G. Morris, Claudio Zamagni, Marco Colleoni, Lorenzo Sica, Denise A. Yardley, Thomas O’Brien, Ayca Gucalp, Laura García-Estévez, Ahmad Awada, Lowell L. Hart, Denka Markova, Eric P. Winer, Lee S. Schwartzberg, Joyce Steinberg, Jamal Tarazi, Vandana G. Abramson, Tiffany A. Traina, Ian E. Krop, Stephen Chan
Publikováno v:
Clinical Cancer Research. 26:6149-6157
Purpose: To determine whether the androgen receptor (AR) inhibitor, enzalutamide, improves effectiveness of endocrine therapy (ET) in hormone receptor–positive (HR+) breast cancer. Patients and Methods: In this phase II trial, patients with HR+/HER
Autor:
M Melé, Serafin Morales, Noelia Martínez, Jordi Canes, Begoña Bermejo, I Garau, Paolo Nuciforo, Patricia Villagrasa, Maria Jose Echarri, Antonia Perelló, Barbara Adamo, Blanca Gonzalez-Farre, Silvia Vazquez, Tomás Pascual, Xavier Gonzalez, Santiago Escrivá-de-Romaní, Patricia Galván, Sonia Pernas, Eva Ciruelos, Mafalda Oliveira, D. Martinez, Javier Cortes, Laia Paré, Alvaro Montaño, Aleix Prat, Eduardo Martínez, Estela Vega, Luis Manso
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CLINICAL CANCER RESEARCH
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
r-INCLIVA. Repositorio Institucional de Producción Científica de INCLIVA
instname
CLINICAL CANCER RESEARCH
r-FHPC. Repositorio Institucional de Producción Científica de la Fundación del Hospital Provincial de Castellón
Purpose:To assess palbociclib in combination with trastuzumab with or without endocrine therapy in patients with HER2-positive advanced breast cancer.Patients and Methods:PATRICIA is a prospective, open-label, multicenter phase II trial. Patients had
Autor:
Ian W. Flinn, Emily Liu, William G. Wierda, Richard R. Furman, Jan A. Burger, Susan O'Brien, James P. Dean, John C. Byrd, Ying Luan, Jeff P. Sharman, Steven Coutre, Weiqiang Zhao, Nyla A. Heerema, Kristie A. Blum
Publikováno v:
Clin Cancer Res
Purpose: The safety and efficacy of ibrutinib, a once-daily Bruton's tyrosine kinase (BTK) inhibitor, in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) was demonstrated in this phase Ib/II study. Extended follow-up up to 8 years is
Autor:
Sylvan C. Baca, Sabina Signoretti, Abdallah Flaifel, Sachet A. Shukla, Pier Vitale Nuzzo, Matthew L. Freedman, Guru Sonpavde, Jacob E. Berchuck, Heng Du, Mark M. Awad, Amin Nassar, Natalie I. Vokes, Yvonne Y. Li, Sarah Abou Alaiwi, John A. Steinharter, Marios Giannakis, Ronan Flippot, Toni K. Choueiri, Wanling Xie, Robert I. Haddad, David J. Kwiatkowski, Taiwen Li, David A. Braun, Eliezer M. Van Allen, Andrew D. Cherniack, X. Shirley Liu, Cigall Kadoch, F. Stephen Hodi, Claire A. Margolis, Ziad Bakouny, Liam F. Spurr, Tarek H. Mouhieddine
Publikováno v:
Cancer Immunol Res
Prior data have variably implicated the inactivation of the mammalian SWItch/Sucrose Non-Fermentable (mSWI/SNF) complex with increased tumor sensitivity to immune checkpoint inhibitors (ICI). Herein, we examined the association between mSWI/SNF varia
Autor:
A. Mendes, L. Aguarin, Keith A. Cengel, Gary D. Kao, William P. Levin, Charles B. Simone, Abigail T. Berman, S. Jean-Baptiste, Melissa A. Frick, Stephen M. Hahn, Steven J. Feigenberg, Samuel Swisher-McClure, Jay F. Dorsey, C. Chinniah
Publikováno v:
Clin Cancer Res
Purpose: Although stereotactic body radiotherapy (SBRT) is effective in early-stage non–small cell lung cancer (NSCLC), approximately 10%–15% of patients will fail regionally and 20%–25% distantly. We evaluate a novel circulating tumor cell (CT